SMARCA2 and posterior cortical atrophy: To validate that these transcriptomic findings translated into differences in protein expression, we performed immunohistochemistry (IHC) on patient samples and confirmed higher SMARCA4 (BRG1) and lower SMARCA2 (BRM) expression with increasing PCa disease progression, with highest SMARCA4 expression observed in CRPC-NE (Fig. 1d and Supplementary Fig. 4).